

Contents

Chapter 1	Type 2 Diabetes: Disease Overview	1
	<i>Daniel M. Kemp</i>	
1.1	Type 2 Diabetes	1
1.1.1	Societal and Economic Effects	1
1.1.2	Epidemiology	2
1.1.3	Pathophysiology	3
1.1.4	Etiology	4
1.2	Treatment of Type 2 Diabetes	5
1.2.1	Lifestyle Management	5
1.2.2	Surgical Intervention	6
1.2.3	Current Drug Therapy Options	6
1.2.4	Emerging Mechanisms	9
1.2.5	Summary of Oral Diabetes Medications	12
	References	13
Chapter 2	Marketed Small Molecule Dipeptidyl Peptidase IV (DPP4) Inhibitors as a New Class of Oral Anti-Diabetics	15
	<i>Zhonghua Pei</i>	
2.1	Introduction	15
2.2	Marketed DPP4 Inhibitors	18
2.3	Potency and Selectivity of Marketed DPP4 Inhibitors	19
2.4	Binding Mode of DPP4 Inhibitors	21
2.5	Pharmacokinetics, Efficacy, and Safety of Marketed DPP4 Inhibitors	23
2.6	Summary	24
	References	25

RSC Drug Discovery Series No. 27

New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches

Edited by Robert M. Jones

© The Royal Society of Chemistry 2012

Published by the Royal Society of Chemistry, www.rsc.org

Chapter 3	SGLT2 Inhibitors in Development	29
	<i>William N. Washburn</i>	
3.1	Introduction	29
3.2	Renal Recovery of Glucose	30
3.3	SGLT2 Inhibitors	31
3.3.1	Target Validation	31
3.3.2	<i>O</i> -Glucosides	32
3.3.3	Biological Assays	34
3.3.4	<i>C</i> -Glucosides	35
3.3.5	Non-Glycoside Containing SGLT2 inhibitors	70
3.4	Clinical Studies with SGLT2 Inhibitors	71
3.4.1	Clinical Evaluation of <i>O</i> -Glucosides	72
3.4.2	Clinical Evaluation of <i>C</i> -Glucosides	73
3.4.3	Antisense Inhibitors of SGLT2	79
3.5	Conclusion	80
	References	80
Chapter 4	Glucokinase Activators in Development	88
	<i>Kevin J. Filipski, Benjamin D. Stevens and Jeffrey A. Pfeifferkorn</i>	
4.1	Introduction	88
4.2	The Role of Glucokinase in the Regulation of Glucose Homeostasis	89
4.3	Genetic Evidence for the Importance of Glucokinase in Diabetes	90
4.4	Small Molecule Glucokinase Activation: Opportunities and Challenges	90
4.5	Clinical Development Status of Glucokinase Activators	91
4.5.1	Advinus Glucokinase Activators	91
4.5.2	Array Biopharma / Amgen Glucokinase Activators	92
4.5.3	AstraZeneca Glucokinase Activators	93
4.5.4	Merck Glucokinase Activators	95
4.5.5	OSI Prosidion / Eli Lilly Glucokinase Activators	96
4.5.6	Pfizer Glucokinase Activators	97
4.5.7	Roche Glucokinase Activators	98
4.5.8	Takeda Glucokinase Activators	99
4.5.9	TransTech Pharma / Novo Nordisk / Forest Laboratories Glucokinase Activators	99
4.5.10	Zydus Cadila Glucokinase Activators	100
	References	100

Chapter 5	11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors in Development	109
	<i>James S. Scott and Jasen Chooramun</i>	
5.1	Introduction to 11 β -Hydroxysteroid Dehydrogenase Type 1 (11 β -HSD1)	109
5.1.1	Glucocorticoids and the Metabolic Syndrome	109
5.1.2	Role, Function, and Structure of 11 β -HSD1	110
5.1.3	Preclinical evidence for 11 β -HSD1 in Treatment of the Metabolic Syndrome	111
5.1.4	The Hypothalamic-Pituitary-Adrenal (HPA) Axis	112
5.1.5	Carbenoxolone (CBX)	112
5.2	Overview of 11 β -HSD1 Inhibitors in Development	113
5.3	11 β -HSD1 Inhibitors by Company	115
5.3.1	Amgen / Biovitrum	115
5.3.2	Merck	120
5.3.3	Pfizer	124
5.3.4	Incyte	125
5.3.5	AstraZeneca	126
5.3.6	Vitae Pharmaceuticals / Boehringer Ingelheim	127
5.3.7	Wyeth	129
5.3.8	Bristol-Myers-Squibb	130
5.3.9	Roche	131
5.3.10	Japan Tobacco / Akros Pharma	131
5.3.11	Lilly	131
5.3.12	Other Companies and Institutions	132
5.4	Conclusions	132
	Acknowledgements	133
	References	133
Chapter 6	Recent Advances in PTP1B Inhibitor Development for the Treatment of Type 2 Diabetes and Obesity	142
	<i>Rongjun He, Li-Fan Zeng, Yantao He and Zhong-Yin Zhang</i>	
6.1	Introduction	142
6.2	Biochemistry of PTP1B	143
6.3	Association of PTP1B with Type 2 Diabetes and Obesity	145
6.3.1	PTP1B in Insulin Signaling	145
6.3.2	PTP1B in Leptin Signaling	147
6.4	Development of PTP1B Inhibitors	148
6.4.1	Phosphonic Acid and F2PMP Derivatives	149
6.4.2	Carboxylic Acids	150
6.4.3	Sulfonic Acids	154
6.4.4	Imides	155

6.4.5	Neutral Molecules	157
6.4.6	Natural Products	160
6.5	Clinic Development of PTP1B Inhibitors	165
6.6	Conclusions and Perspectives	166
	Acknowledgment	167
	References	167
Chapter 7	Recent Advances in the Discovery of GPR119 Agonists	177
	<i>Unmesh Shah, Scott Edmondson and Jason W. Szewczyk</i>	
7.1	Introduction	177
7.2	GPR119: Receptor Expression, Signaling, and Deorphanization	178
7.3	Prototype Small-Molecule GPR119 Agonists and Glucose Homeostasis	180
7.4	GPR119 Agonists: Medicinal Chemistry	182
7.4.1	Arena Pharmaceuticals	182
7.4.2	Prosidion Ltd.	186
7.4.3	Metabolex	189
7.4.4	GlaxoSmithKline	190
7.4.5	Merck and Co.	192
7.4.6	Novartis	195
7.4.7	Bristol-Myers Squibb	197
7.4.8	Boehringer Ingelheim	197
7.4.9	Pfizer	198
7.4.10	Astellas	200
7.4.11	Cadila Healthcare	201
7.5	Clinical Status of GPR119 agonists	201
7.5.1	APD668 and APD597	202
7.5.2	PSN821	202
7.5.3	MBX2982	203
7.5.4	GSK1292263	203
7.6	Summary	204
	Acknowledgment	206
	References	207
Chapter 8	Acyl-CoA:Diacylglycerol Acyltransferase-1 Inhibition as an Approach to the Treatment of Type 2 Diabetes	215
	<i>Robert L. Dow</i>	
8.1	Introduction	215
8.2	Characterization of DGAT Enzymes	218
8.2.1	DGAT Enzymatic Activity	218
8.2.2	Cloning of DGAT Enzymes	219

8.2.3	Structural Characterization of DGAT-1	219
8.3	Role of DGAT-1 in Tissue Physiology and Disease States	220
8.3.1	Tissue Distribution of DGAT Enzymes	220
8.3.2	Role of DGAT-1 in Intestine	220
8.3.3	Role of DGAT-1 in Liver	222
8.3.4	Role of DGAT-1 in Adipose Tissue	223
8.3.5	Role of DGAT-1 in Muscle	224
8.3.6	Role of DGAT-1 in Hepatitis C Infectivity	226
8.4	DGAT-1 Inhibitors	227
8.4.1	Biarylamines	227
8.4.2	Ureas	230
8.4.3	Amides	232
8.4.4	Aminopyrimidines	235
8.4.5	Additional Lead Series	238
8.5	Human Clinical Trials with DGAT-1 Inhibitors	238
8.6	Conclusion	240
	Acknowledgment	241
	References	241

Chapter 9 Stearoyl-CoA Desaturase 1 (SCD1) Inhibitors: Bench to Bedside Must Only Go Through Liver **249**
Gang Liu

9.1	Introduction	249
9.1.1	Type 2 Diabetes, Obesity, and Dyslipidemia Epidemics	249
9.1.2	Stearoyl-CoA Desaturases	250
9.2	Target Validation	251
9.2.1	Target Validation in Rodents	251
9.2.2	Adverse Events Associated with SCD Gene Deletion	252
9.2.3	Human Correlation	254
9.3	First-Generation Systemically Distributed SCD Inhibitors	254
9.3.1	Novel SCD Inhibitors	254
9.3.2	Pharmacology and Adverse Events	260
9.4	Second-Generation Liver-Targeted SCD Inhibitors	262
9.4.1	Passively Liver Selective Inhibitors	262
9.4.2	SCD Inhibitors Actively Transported into Liver	262
9.4.3	Pharmacological Characterization of Liver-Targeted SCD Inhibitors	264
9.5	Conclusions	264
	References	265

Chapter 10	TGR5 Agonists in Development	270
	<i>Antonio Macchiarulo, Antimo Gioiello and Roberto Pellicciari</i>	
10.1	Introduction	270
10.2	TGR5 at a Glance	271
	10.2.1 Early Pharmacological Characterization	271
	10.2.2 Sequence, Structure, and Gene Variants	271
10.3	Expression and Physiological Functions	273
	10.3.1 TGR5 in Brown Adipose Tissue (BAT) and Skeletal Muscle: Control of Energy Homeostasis and Body Weight	273
	10.3.2 TGR5 in the Intestine: Control of Glucose Metabolism and Insulin Sensitivity	276
	10.3.3 TGR5 in Monocytes and Macrophages: Immunosuppressive Properties	277
	10.3.4 TGR5 Functions in Other Tissues	278
10.4	TGR5 Modulation as Therapeutic Opportunity in Type 2 Diabetes (T2D)	280
10.5	Ligands in Development	281
	10.5.1 Classification of TGR5 Ligands	281
	10.5.2 Steroidal and Non-Steroidal TGR5 Ligands in the Drug-like Property Space	294
10.6	Predictive Models of TGR5 Affinity	295
10.7	Conclusions	298
10.8	References	300
Chapter 11	The Discovery and Development of MB07803, a Second-Generation Fructose-1,6-bisphosphatase Inhibitor with Improved Pharmacokinetic Properties, as a Potential Treatment of Type 2 Diabetes	306
	<i>Qun Dang, Paul D. van Poelje and Mark D. Erion</i>	
11.1	Introduction	306
11.2	Discovery of First-Generation FBPase Inhibitor	308
	11.2.1 Discovery of MB06322, First Oral FBPase Inhibitor	308
	11.2.2 Clinical Studies	309
	11.2.3 <i>N</i> -Acetylation and Possible Impact of <i>N</i> -Acetylated Metabolites on Mitochondrial Function	310
11.3	Design Strategy for Second-Generation FBPase Inhibitors	312
	11.3.1 SAR Summary for FBPase Inhibition by the Thiazole Scaffold	312

11.3.2	Design Strategies to Reduce or Eliminate <i>N</i> -Acetylation	312
11.4	Discovery of a Second-Generation FBPase Inhibitor: MB07803	314
11.4.1	Investigation of C5 Steric Effects of the Thiazole Scaffold on <i>N</i> -Acetylation	314
11.4.2	Exploration of C5 Electronic Effects of the Thiazole Scaffold: Discovery of MB07729	315
11.4.3	Oral Delivery of FBPase Inhibitors with no NAT Liability: Prodrug SAR	316
11.5	Development of MB07803 (6j)	317
11.5.1	Efficacy Studies of MB07803 (6j) in Animal Models of T2DM	317
11.5.2	Phase I/II Clinical Studies	319
11.6	Summary	321
	References	322
Chapter 12	Inhibition of Glycogen Phosphorylase as a Strategy for the Treatment of Type 2 Diabetes	324
	<i>Brad R. Henke</i>	
12.1	Introduction	324
12.2	Characteristics of Glycogen Phosphorylase	325
12.2.1	Structure, Function, and Regulation of Glycogen Phosphorylase	325
12.2.2	Inhibitor Binding Sites of Glycogen Phosphorylase	327
12.3	Glycogen Phosphorylase Inhibitors	329
12.3.1	<i>In vitro</i> and <i>in vivo</i> Assessment of GP Inhibition	329
12.3.2	Catalytic Site Inhibitors	331
12.3.3	Glycogen Storage Site Inhibitors	334
12.3.4	Purine Nucleoside Site Inhibitors	335
12.3.5	AMP Site Inhibitors	336
12.3.6	Indole Site Inhibitors	345
12.3.7	Inhibitors of the GP-G _L Interaction	351
12.3.8	Inhibitors with an Unknown Binding Mode	351
12.4	GP Inhibitors as Therapeutic Agents for Type 2 Diabetes	354
12.4.1	Clinical Results with GP Inhibitors	354
12.4.2	Challenges with GP Inhibitors	355
12.4.3	Opportunities for GP Inhibitors	358
12.5	Conclusions	359
	Acknowledgment	360
	References	360

Chapter 13	SIRT1 Activators in Development	366
	<i>Robert B. Perni, Vipin Suri, Thomas V. Riera, Joseph Wu, Charles A. Blum, George P. Vlasuk and James L. Ellis</i>	
13.1	Introduction	366
13.2	Role of SIRT1 in Metabolic Regulation	367
13.2.1	SIRT1 and Regulation of Energy Balance	370
13.2.2	SIRT1 and Carbohydrate Metabolism	371
13.2.3	SIRT1 and Lipid Metabolism	372
13.2.4	SIRT1 and Insulin Secretion and Sensitivity	374
13.2.5	SIRT1 and Other Hormones	375
13.3	Biochemistry of SIRT1 Activation	376
13.3.1	General Characterization of Enzyme Activation	376
13.3.2	Demonstration of Direct Activation of SIRT1 by STACs	377
13.4	The Medicinal Chemistry of SIRT1 Activators	381
13.4.1	Polyphenols	381
13.4.2	Isoflavones	382
13.4.3	Dihydropyridines	382
13.4.4	Dihydroquinolones	383
13.4.5	Oxazolopyridines and Related Analogs	383
13.4.6	Imidazothiazoles, Thiazaolopyridines, and Related Analogs	385
13.4.7	Newly Disclosed Activators	386
13.5	Preclinical Studies with SIRT1 Activators	390
13.5.1	SIRT1 Dependence of SIRT1 Modulators	392
13.6	Conclusion	394
	References	395
Chapter 14	Long-Chain Free Fatty Acid Receptor Agonists	403
	<i>Jonathan B. Houze</i>	
14.1	Introduction: Diabetes and Free Fatty Acids	403
14.2	Free Fatty Acid Receptors	404
14.2.1	Biology of FFA1	404
14.2.2	Biology of GPR120	409
14.3	FFA1 Receptor Agonists	411
14.3.1	Open Chain Carboxylic Acids	412
14.3.2	Open Chain Carboxylate Bioisosteres	413
14.3.3	Bicyclic Carboxylates and Carboxylate Bioisosteres	415
14.3.4	Tricyclic Carboxylates and Carboxylate Bioisosteres	418
14.4	GPR120 Receptor Agonists	419
14.4.1	Carboxylic Acids	419
14.4.2	Carboxylate Bioisosteres	421
14.5	Conclusions	422
	References	422

Chapter 15	Glucagon Receptor Antagonists in Development	429
	<i>Duane E. DeMong and M. W. Miller</i>	
15.1	Introduction	429
15.2	Peptide Glucagon Receptor Antagonists	430
15.3	Monoclonal Antibodies	430
15.4	Small Molecule Glucagon Receptor Antagonists	431
15.4.1	β -Alanine Benzamides and their Isosteres	431
15.4.2	Biaryl Glucagon Receptor Antagonists	452
15.4.3	Phenol-Based hGCGR Antagonists	452
15.4.4	Additional Small Molecule hGCGR Antagonists	454
15.5	Conclusions	457
	References	457
Chapter 16	ACC Inhibitors in Development	464
	<i>Matthew P. Bourbeau</i>	
16.1	Introduction	464
16.2	ACC2 Mouse Knockout Studies	465
16.2.1	Wakil's Studies	465
16.2.2	Cooney's Studies	468
16.2.3	Lowell's Studies	469
16.2.4	Summary of ACC2 Knockout Data	470
16.3	ACC1 Knockout Studies	471
16.3.1	Total ACC1 Knockout	471
16.3.2	Tissue-Specific ACC1 Knockout: Wakil	471
16.3.3	Tissue-Specific ACC1 Knockout: Kusunoki	472
16.3.4	Summary of ACC1 Knockout Data	472
16.4	ACC as a Target for Cancer Treatment	473
16.5	ACC Inhibitors for the Treatment of Metabolic Syndrome	473
16.5.1	Pfizer's ACC Inhibitors	473
16.5.2	Abbott's ACC Inhibitors	479
16.5.3	Tashio's ACC Inhibitors	482
16.5.4	Torrent's ACC Inhibitors	485
16.5.5	Cropsolutions' ACC Inhibitors	486
16.5.6	Sanofi-Aventis' ACC Inhibitors	488
16.5.7	Astra Zeneca's ACC Program	490
16.5.8	Other ACC Inhibitors with <i>in vivo</i> Data: Soraphen A	493
16.5.9	Other ACC Inhibitors of Note	495
16.6	Conclusions	495
	References	496
	Subject Index	501